Study highlights
- Participants will be able to continue their treatment with Enzyme Replacement Therapy (ERT) as needed
- This study is recruiting male and female Fabry patients
- Participants will not be required to undergo pre-conditioning chemotherapy
The STAAR study has been designed to investigate the potential of an investigational gene therapy called ST-920 to treat men and women living with Fabry disease.
You are currently viewing the UK version of the website
To view another version of this site, please select your country from the list below:
The site you are entering is not the property of, nor managed by, Sangamo Therapeutics. Sangamo Therapeutics assumes no responsibility for the content of sites not managed by Sangamo Therapeutics. Furthermore, Sangamo Therapeutics is not responsible for, nor does it have control over, the privacy policies of these sites.